SGLT2 inhibitor treatment in patients with type 2 diabetes and acute myocardial infarction was associated with a significantly lower incidence of intra-stent restenosis-related major adverse cardiovascular events (HR 0.418) compared to never-users, independent of glycemic control.
Observational (n=377)
Does SGLT2 inhibitor treatment reduce intra-stent restenosis-related major adverse cardiovascular events in patients with type 2 diabetes and acute myocardial infarction undergoing PCI?
SGLT2 inhibitors are associated with a significantly reduced risk of in-stent restenosis-related cardiovascular events in patients with type 2 diabetes undergoing PCI for acute myocardial infarction, independent of glycemic control.
Hazard Ratio: 0.418 (95% CI 0.241–0.725)
Absolute Event Rate: 10.2% vs 22.1%
p-value: p=0.002
BACKGROUND: No study evaluated the incidence of intra-stent restenosis (ISR)-related events in patients with type 2 diabetes (T2DM) and acute myocardial infarction (AMI) treated or not with sodium/glucose cotransporter 2 inhibitors (SGLT2i). METHODS: We recruited 377 patients with T2DM and AMI undergoing percutaneous coronary intervention (PCI). Among them, 177 T2DM were treated with SGLT2 inhibitors before PCI. The primary outcome was major adverse cardiovascular events (MACE) defined as cardiac death, re-infarction, and heart failure related to ISR. In patients without ISR, minimal lumen area and minimal lumen diameter were assessed by coronary CT-angiography at 1-year follow-up. RESULTS: Glycemic control was similar in SGLT2i-treated patients and never SGLT2i-users. The incidence of ISR-related MACE was higher in never SGLT2i-users compared with SGLT2i-treated patients, an effect independent of glycemic status (HR = 0.418, 95% CI = 0.241-0.725, P = 0.002) and observed also in the subgroup of patients with HbA1c < 7% (HR = 0.393, 95% CI = 0.157-0.984, P = 0.027). In patients without the event, the stent patency was greater in SGLT2i-treated patients compared with never SGLT2i-users at 1-year follow-up. CONCLUSIONS: SGLT2i treatment in T2DM is associated with a reduced incidence of ISR-related events, independently of glycemic control.
Marfella et al. (Fri,) conducted a observational in Type 2 diabetes and acute myocardial infarction (n=377). SGLT2 inhibitors vs. Never SGLT2i-users was evaluated on Major adverse cardiovascular events (MACE) defined as cardiac death, re-infarction, and heart failure related to intra-stent restenosis (ISR) (HR 0.418, 95% CI 0.241-0.725, p=0.002). SGLT2 inhibitor treatment in patients with type 2 diabetes and acute myocardial infarction was associated with a significantly lower incidence of intra-stent restenosis-related major adverse cardiovascular events (HR 0.418) compared to never-users, independent of glycemic control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: